interactions:
- request:
    body: tool=biocommons.eutils._internal&email=biocommons-dev%40googlegroups.com&retmode=xml&usehistory=y&retmax=250&db=pubmed&id=29915538
    headers:
      Accept:
      - '*/*'
      Accept-Encoding:
      - gzip, deflate
      Connection:
      - keep-alive
      Content-Length:
      - '130'
      Content-Type:
      - application/x-www-form-urlencoded
      User-Agent:
      - python-requests/2.31.0
    method: POST
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi
  response:
    body:
      string: '<?xml version="1.0" ?>

        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January
        2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">

        <PubmedArticleSet>

        <PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID
        Version="1">29915538</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article
        PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue
        CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Frontiers
        in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Efficacy
        and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes:
        A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</ArticleTitle><Pagination><StartPage>576</StartPage><MedlinePgn>576</MedlinePgn></Pagination><ELocationID
        EIdType="pii" ValidYN="Y">576</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2018.00576</ELocationID><Abstract><AbstractText><b>Background:</b>
        Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
        agonist, has showed a favorable effect on glycaemic control and weight reduction
        in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to evaluate
        the clinical efficacy and safety of semaglutide in T2DM. <b>Methods:</b> A
        comprehensive searching was performed for Phase III randomized controlled
        trials (RCTs) which reported the efficacy and safety data of semaglutide and
        other therapies. The efficacy data expressed as weight mean difference (WMD)
        and the safety data expressed as risk ratios (RRs) were calculated by employing
        random-effects model. Heterogeneity was assessed through I<sup>2</sup> test,
        and subgroup analyses were performed by different control groups, dosage of
        semaglutide, and durations of follow up. <b>Results:</b> 9 RCTs including
        9,773 subjects met the inclusion criteria. For efficacy, compared with other
        therapies, semaglutide resulted in a significant reduction in glycosylated
        hemoglobin (weight mean difference, WMD: -0.93%, 95% CI: -1.24 to -0.62, <i>P</i>
        &lt; 0.001), fasting plasma glucose (WMD: -1.15 mmol/L, 95% CI: -1.67 to -0.63,
        <i>P</i> &lt; 0.001), mean self-monitoring of plasma glucose (WMD: -1.19 mmol/L,
        95% CI: -1.68 to -0.70, <i>P</i> &lt; 0.001), body weight (WMD: -3.47 kg,
        95% CI: -3.96 to -2.98, <i>P</i> &lt; 0.001), body mass index (WMD: -1.25
        kg/m<sup>2</sup>, 95% CI: -1.45 to -1.04, <i>P</i> &lt; 0.001), systolic blood
        pressure (WMD: -2.55 mmHg, 95% CI: -3.22 to -1.88, <i>P</i> &lt; 0.001), with
        the exception of negative result of diastolic blood pressure (WMD: -0.29 mmHg,
        95% CI: -0.65 to 0.07, <i>P</i> = 0.113) and increased impact on pulse rate
        (WMD: -2.21, 95% CI: 1.54 to 2.88, <i>P</i> &lt; 0.001). The results were
        consistent across the key subgroups. For safety, semaglutide did not increase
        the risk of any adverse events, hypoglycemia and pancreatitis, but induced
        a higher risk of gastrointestinal disorders when compared with other therapies
        (RR: 1.98, 95%CI: 1.49 to 2.62, <i>P</i> &lt; 0.001). <b>Conclusion:</b> Semaglutide
        was effective and acceptable in patients with T2DM except for a high risk
        of gastrointestinal disorders. The capacity of glycaemic and body weight control
        of semaglutide appeared more effective than other add-on therapies including
        other GLP-1 receptor agonists of exenatide release and dulaglutide.</AbstractText></Abstract><AuthorList
        CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Fang-Hong</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University,
        Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Shanghai Children''s Medical Center, School of Medicine, Shanghai
        Jiaotong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author
        ValidYN="Y"><LastName>Cui</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University,
        Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zai-Li</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University,
        Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zhi-Chun</ForeName><Initials>ZC</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University,
        Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao-Yan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department
        of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University,
        Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType
        UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate
        DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front
        Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList
        Owner="NOTNLM"><Keyword MajorTopicYN="N">glucagon-like peptide-1 receptor
        agonists</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword
        MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">semaglutide</Keyword><Keyword
        MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate
        PubStatus="received"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate
        PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate
        PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate
        PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate
        PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate
        PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId
        IdType="pubmed">29915538</ArticleId><ArticleId IdType="pmc">PMC5994433</ArticleId><ArticleId
        IdType="doi">10.3389/fphar.2018.00576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmann
        A. J., Capehorn M., Charpentier G., Dotta F., Henkel E., Lingvay I. (2018).
        Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects
        with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical
        trial. Diabetes Care 41, 258&#x2013;266. 10.2337/dc17-0417</Citation><ArticleIdList><ArticleId
        IdType="doi">10.2337/dc17-0417</ArticleId><ArticleId IdType="pubmed">29246950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahr&#xe9;n
        B., Masmiquel L., Kumar H., Sargin M., Karsb&#xf8;l J. D., Jacobsen S. H.,
        et al. . (2017). Efficacy and safety of once-weekly semaglutide versus once-daily
        sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients
        with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised
        trial. Lancet Diabetes Endocrinol. 5, 341&#x2013;354. 10.1016/S2213-8587(17)30092-X</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S2213-8587(17)30092-X</ArticleId><ArticleId IdType="pubmed">28385659</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroda
        V. R., Bain S. C., Cariou B., Piletic M., Rose L., Axelsen M., et al. . (2017).
        Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine
        as add-on to metformin (with or without sulfonylureas) in insulin-naive patients
        with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group,
        multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 5,
        355&#x2013;366. 10.1016/S2213-8587(17)30085-2</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S2213-8587(17)30085-2</ArticleId><ArticleId IdType="pubmed">28344112</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler
        P. C., Elashoff M., Elashoff R., Gale E. A. M. (2013). A critical analysis
        of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?
        Diabetes Care 36, 2118&#x2013;2125. 10.2337/dc12-2713</Citation><ArticleIdList><ArticleId
        IdType="doi">10.2337/dc12-2713</ArticleId><ArticleId IdType="pmc">PMC3687282</ArticleId><ArticleId
        IdType="pubmed">23645885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen
        Y. H., Lin H., Xie C. L., Hou J. W., Li Y. G. (2017). Role of adenosine-guided
        pulmonary vein isolation in patients undergoing catheter ablation for atrial
        fibrillation: a meta-analysis. Europace 19, 552&#x2013;559. 10.1093/europace/euw201</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1093/europace/euw201</ArticleId><ArticleId IdType="pubmed">28431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway
        R., Rodbard H., Lingvay I., Reed J., Rosa R. D., Rose L., et al. (2016). Efficacy
        and safety of semaglutide once-weekly vs. placebo as add-on to basal insulin
        alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN
        5). Can. J. Diabetes 40, S41&#x2013;S42. 10.1016/j.jcjd.2016.08.116</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.jcjd.2016.08.116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon
        S. (2018). Semaglutide: first global approval. Drugs 78, 275&#x2013;284. 10.1007/s40265-018-0871-0</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1007/s40265-018-0871-0</ArticleId><ArticleId IdType="pubmed">29363040</ArticleId></ArticleIdList></Reference><Reference><Citation>Doggrell
        S. A. (2018). Sgemaglutide in type 2 diabetes - is it the best glucagon-like
        peptide 1 receptor agonist (GLP-1R agonist)? Expert Opin. Drug Metab. Toxicol.
        14, 371&#x2013;377. 10.1080/17425255.2018.1441286</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1080/17425255.2018.1441286</ArticleId><ArticleId IdType="pubmed">29439603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugan
        J. A. (2017). Standards of care and treatment in diabetes. Phys. Assist. Clin.
        2, 13&#x2013;23. 10.1016/j.cpha.2016.08.004</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.cpha.2016.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dungan
        K. M., Povedano S. T., Forst T., Gonz&#xe1;lez J. G., Atisso C., Sealls W.,
        et al. . (2014). Once-weekly dulaglutide versus once-daily liraglutide in
        metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label,
        phase 3, non-inferiority trial. Lancet 384, 1349&#x2013;1357. 10.1016/S0140-6736(14)60976-4</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S0140-6736(14)60976-4</ArticleId><ArticleId IdType="pubmed">25018121</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger
        M., Davey Smith G., Schneider M., Minder C. (1997). Bias in meta-analysis
        detected by a simple, graphical test. BMJ 315, 629&#x2013;634. 10.1136/bmj.315.7109.629</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId
        IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca
        V., Capehorn M., Garg S., Jodar E., Birch S., Holst A. G., et al. (2017).
        Semaglutide-induced reductions in insulin resistance are mediated primarily
        via weight loss in subjects with type 2 diabetes (SUSTAIN 1-3). Diabetologia
        60, S375&#x2013;S376.</Citation></Reference><Reference><Citation>Giorda C.
        B., Sacerdote C., Nada E., Marafetti L., Baldi I., Gnavi R. (2015). Incretin-based
        therapies and acute pancreatitis risk: a systematic review and meta-analysis
        of observational studies. Endocrine 48, 461&#x2013;471. 10.1007/s12020-014-0386-8</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1007/s12020-014-0386-8</ArticleId><ArticleId IdType="pubmed">25146552</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins
        J. P., Altman D. G., G&#xf8;tzsche P. C., J&#xfc;ni P., Moher D., Oxman A.
        D., et al. . (2011). The Cochrane Collaboration''s tool for assessing risk
        of bias in randomised trials. BMJ 343:d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId
        IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi
        S. E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M.,
        et al. . (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered
        approach: position statement of the American Diabetes Association (ADA) and
        the European Association for the Study of Diabetes (EASD). Diabetes Care 35,
        1364&#x2013;1379. 10.2337/dc12-0413</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-0413</ArticleId><ArticleId
        IdType="pmc">PMC3357214</ArticleId><ArticleId IdType="pubmed">22517736</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi
        S. E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M.,
        et al. . (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered
        approach: update to a position statement of the American Diabetes Association
        and the European Association for the Study of Diabetes. Diabetes Care 38,
        140&#x2013;149. 10.2337/dc14-2441</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-2441</ArticleId><ArticleId
        IdType="pubmed">25538310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ja&#xef;s
        X., D''Armini A. M., Jansa P., Torbicki A., Delcroix M., Ghofrani H. A., et
        al. . (2008). Bosentan for treatment of inoperable chronic thromboembolic
        pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable forms of chronIc
        Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
        J. Am. Coll. Cardiol. 52, 2127&#x2013;2134. 10.1016/j.jacc.2008.08.059</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.jacc.2008.08.059</ArticleId><ArticleId IdType="pubmed">19095129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku
        K., Yamada Y., Watada H., Abiko A., Nishida T., Zacho J., et al. . (2018).
        Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic
        drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized
        trial. Diabetes Obes. Metab. 20, 1202&#x2013;1212. 10.1111/dom.13218</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1111/dom.13218</ArticleId><ArticleId IdType="pmc">PMC5969242</ArticleId><ArticleId
        IdType="pubmed">29322610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitza
        C., Dahl K., Jacobsen J. B., Axelsen M. B., Flint A. (2017). Effects of semaglutide
        on beta cell function and glycaemic control in participants with type 2 diabetes:
        a randomised, double-blind, placebo-controlled trial. Diabetologia 60, 1390&#x2013;1399.
        10.1007/s00125-017-4289-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4289-0</ArticleId><ArticleId
        IdType="pmc">PMC5491562</ArticleId><ArticleId IdType="pubmed">28526920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitza
        C., Nosek L., Jensen L., Hartvig H., Jensen C. B., Flint A. (2015). Semaglutide,
        a once-weekly human GLP-1 analog, does not reduce the bioavailability of the
        combined oral contraceptive, ethinylestradiol/levonorgestrel. J. Clin. Pharmacol.
        55, 497&#x2013;504. 10.1002/jcph.443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.443</ArticleId><ArticleId
        IdType="pmc">PMC4418331</ArticleId><ArticleId IdType="pubmed">25475122</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannis
        T., Liakos A. (2015). Efficacy and safety of once-weekly glucagon-like peptide
        1 receptor agonists for the management of type 2 diabetes: a systematic review
        and meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 17,
        1065&#x2013;1074. 10.1111/dom.12541</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12541</ArticleId><ArticleId
        IdType="pubmed">26395850</ArticleId></ArticleIdList></Reference><Reference><Citation>Koro
        C. E., Bowlin S. J., Bourgeois N., Fedder D. O. (2004). Glycemic control from
        1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary
        report. Diabetes Care 27, 17&#x2013;20. 10.2337/diacare.27.1.17</Citation><ArticleIdList><ArticleId
        IdType="doi">10.2337/diacare.27.1.17</ArticleId><ArticleId IdType="pubmed">14693960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau
        J., Bloch P., Sch&#xe4;ffer L., Pettersson I., Spetzler J., Kofoed J., et
        al. . (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1)
        analogue semaglutide. J. Med. Chem. 58, 7370&#x2013;7380. 10.1021/acs.jmedchem.5b00726</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1021/acs.jmedchem.5b00726</ArticleId><ArticleId IdType="pubmed">26308095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee
        Y. S., Park M. S., Choung J. S., Kim S. S., Oh H. H., Choi C. S., et al. .
        (2012). Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration
        and inflammation in an obese mouse model of diabetes. Diabetologia 55, 2456&#x2013;2468.
        10.1007/s00125-012-2592-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2592-3</ArticleId><ArticleId
        IdType="pubmed">22722451</ArticleId></ArticleIdList></Reference><Reference><Citation>Li
        L., Shen J., Bala M. M., Busse J. W., Ebrahim S., Vandvik P. O., et al. .
        (2014). Incretin treatment and risk of pancreatitis in patients with type
        2 diabetes mellitus: systematic review and meta-analysis of randomised and
        non-randomised studies. BMJ 348:g2366. 10.1136/bmj.g2366</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1136/bmj.g2366</ArticleId><ArticleId IdType="pmc">PMC3987051</ArticleId><ArticleId
        IdType="pubmed">24736555</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu
        J., Conde K., Zhang P., Lilascharoen V., Xu Z., Lim B. K., et al. . (2017).
        Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous
        glucagon-like peptide-1 in the paraventricular Hypothalamus. Neuron 96, 897.e895&#x2013;909.e895.
        10.1016/j.neuron.2017.09.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.09.042</ArticleId><ArticleId
        IdType="pmc">PMC5729931</ArticleId><ArticleId IdType="pubmed">29056294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz
        M., Lawson F., Owens D., Raccah D., Roy-Duval C., Lehmann A., et al. . (2017).
        Differential effects of glucagon-like peptide-1 receptor agonists on heart
        rate. Cardiovasc. Diabetol. 16:6. 10.1186/s12933-016-0490-6</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1186/s12933-016-0490-6</ArticleId><ArticleId IdType="pmc">PMC5237337</ArticleId><ArticleId
        IdType="pubmed">28086882</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso
        S. P., Bain S. C., Consoli A., Eliaschewitz F. G., J&#xf3;dar E., Leiter L.
        A., et al. . (2016). Semaglutide and cardiovascular outcomes in patients with
        type 2 diabetes. N. Engl. J. Med. 375, 1834&#x2013;1844. 10.1056/NEJMoa1607141</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier
        J. J. (2012). GLP-1 receptor agonists for individualized treatment of type
        2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728&#x2013;742. 10.1038/nrendo.2012.140</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1038/nrendo.2012.140</ArticleId><ArticleId IdType="pubmed">22945360</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher
        D., Liberati A., Tetzlaff J., Altman D. G. (2010). Preferred reporting items
        for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg.
        8, 336&#x2013;341. 10.1016/j.ijsu.2010.02.007</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.ijsu.2010.02.007</ArticleId><ArticleId IdType="pubmed">20171303</ArticleId></ArticleIdList></Reference><Reference><Citation>Monami
        M., Dicembrini I., Nardini C., Fiordelli I., Mannucci E. (2014). Glucagon-like
        peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized
        clinical trials. Diabetes Res. Clin. Pract. 103, 269&#x2013;275. 10.1016/j.diabres.2014.01.010</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.diabres.2014.01.010</ArticleId><ArticleId IdType="pubmed">24485345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck
        M. A., Petrie J. R., Sesti G., Mannucci E., Courr&#xe8;ges J. P., Lindegaard
        M. L., et al. . (2016). A phase 2, randomized, dose-finding study of the novel
        once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label
        liraglutide in patients with type 2 diabetes. Diabetes Care 39, 231&#x2013;241.
        10.2337/dc15-0165</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-0165</ArticleId><ArticleId
        IdType="pubmed">26358288</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel
        A., MacMahon S., Chalmers J., Neal B., Woodward M., et al. . (2007). Effects
        of a fixed combination of perindopril and indapamide on macrovascular and
        microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE
        trial): a randomised controlled trial. Lancet 370, 829&#x2013;840. 10.1016/S0140-6736(07)61303-8</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S0140-6736(07)61303-8</ArticleId><ArticleId IdType="pubmed">17765963</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratley
        R. E., Aroda V. R., Lingvay I., L&#xfc;demann J., Andreassen C., Navarria
        A., et al. . (2018). Semaglutide versus dulaglutide once weekly in patients
        with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
        Lancet Diabetes Endocrinol. 6, 275&#x2013;286. 10.1016/S2213-8587(18)30024-X</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S2213-8587(18)30024-X</ArticleId><ArticleId IdType="pubmed">29397376</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratley
        R. E., Nauck M. A., Barnett A. H., Feinglos M. N., Ovalle F., Harman-Boehm
        I., et al. . (2014). Once-weekly albiglutide versus once-daily liraglutide
        in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY
        7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
        Lancet Diabetes Endocrinol. 2, 289&#x2013;297. 10.1016/S2213-8587(13)70214-6</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S2213-8587(13)70214-6</ArticleId><ArticleId IdType="pubmed">24703047</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshanov
        P. S., Dennis B. B. (2015). Incretin-based therapies are associated with acute
        pancreatitis: meta-analysis of large randomized controlled trials. Diabetes
        Res. Clin. Pract. 110, e13&#x2013;e17. 10.1016/j.diabres.2015.10.014</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.diabres.2015.10.014</ArticleId><ArticleId IdType="pubmed">26643128</ArticleId></ArticleIdList></Reference><Reference><Citation>Seino
        Y., Terauchi Y., Osonoi T., Yabe D., Abe N., Nishida T., et al. . (2018).
        Safety and efficacy of semaglutide once weekly vs sitagliptin once daily,
        both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes.
        Metab. 20, 378&#x2013;388. 10.1111/dom.13082</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1111/dom.13082</ArticleId><ArticleId IdType="pmc">PMC5813234</ArticleId><ArticleId
        IdType="pubmed">28786547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisti
        L. G., Dajko M., Campanella P., Shkurti E., Ricciardi W., de Waure C. (2017).
        The effect of multifactorial lifestyle interventions on cardiovascular risk
        factors: a systematic review and meta-analysis of trials conducted in the
        general population and high risk groups. Prev. Med. 109, 82&#x2013;97. 10.1016/j.ypmed.2017.12.027</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.ypmed.2017.12.027</ArticleId><ArticleId IdType="pubmed">29291422</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorli
        C., Harashima S. I., Tsoukas G. M., Unger J., Karsb&#xf8;l J. D., Hansen T.,
        et al. . (2017). Efficacy and safety of once-weekly semaglutide monotherapy
        versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind,
        randomised, placebo-controlled, parallel-group, multinational, multicentre
        phase 3a trial. Lancet Diabetes Endocrinol. 5, 251&#x2013;260. 10.1016/S2213-8587(17)30013-X</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/S2213-8587(17)30013-X</ArticleId><ArticleId IdType="pubmed">28110911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun
        F., Chai S., Li L., Yu K., Yang Z., Wu S., et al. . (2015a). Effects of glucagon-like
        peptide-1 receptor agonists on weight loss in patients with type 2 diabetes:
        a systematic review and network meta-analysis. J. Diabetes Res. 2015:157201.
        10.1155/2015/157201</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/157201</ArticleId><ArticleId
        IdType="pmc">PMC4320855</ArticleId><ArticleId IdType="pubmed">25688373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun
        F., Chai S., Yu K., Quan X., Yang Z., Wu S., et al. . (2015b). Gastrointestinal
        adverse events of glucagon-like peptide-1 receptor agonists in patients with
        type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol.
        Ther. 17, 35&#x2013;42. 10.1089/dia.2014.0188</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1089/dia.2014.0188</ArticleId><ArticleId IdType="pmc">PMC4290796</ArticleId><ArticleId
        IdType="pubmed">25375397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun
        F., Wu S., Guo S., Yu K., Yang Z., Li L., et al. . (2015c). Impact of GLP-1
        receptor agonists on blood pressure, heart rate and hypertension among patients
        with type 2 diabetes: a systematic review and network meta-analysis. Diabetes
        Res. Clin. Pract. 110, 26&#x2013;37. 10.1016/j.diabres.2015.07.015</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1016/j.diabres.2015.07.015</ArticleId><ArticleId IdType="pubmed">26358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan
        X., Cao X., Zhou M., Zou P., Hu J. (2017). Efficacy and safety of once-weekly
        semaglutide for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs
        26, 1083&#x2013;1089. 10.1080/13543784.2017.1360274</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1080/13543784.2017.1360274</ArticleId><ArticleId IdType="pubmed">28741970</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner
        R. C., Cull C. A., Frighi V., Holman R. R. (1999). Glycemic control with diet,
        sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:
        progressive requirement for multiple therapies (UKPDS 49). UK Prospective
        Diabetes Study (UKPDS) Group. JAMA 281, 2005&#x2013;2012. 10.1001/jama.281.21.2005</Citation><ArticleIdList><ArticleId
        IdType="doi">10.1001/jama.281.21.2005</ArticleId><ArticleId IdType="pubmed">10359389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang
        L., Zhang M., Zhang Y., Tong N. (2016). Efficacy and safety of dulaglutide
        in patients with type 2 diabetes: a meta-analysis and systematic review. Sci.
        Rep. 6:18904. 10.1038/srep18904</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep18904</ArticleId><ArticleId
        IdType="pmc">PMC4705511</ArticleId><ArticleId IdType="pubmed">26742577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>'
    headers:
      Access-Control-Allow-Origin:
      - '*'
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Cache-Control:
      - private
      Connection:
      - Keep-Alive
      Content-Security-Policy:
      - upgrade-insecure-requests
      Content-Type:
      - text/xml; charset=UTF-8
      Date:
      - Fri, 12 Apr 2024 19:08:05 GMT
      Keep-Alive:
      - timeout=4, max=40
      NCBI-PHID:
      - 322C2F91E09EF72500004833F145B7AD.1.1.m_5
      NCBI-SID:
      - 9E7725A350D33AFB_E812SID
      Referrer-Policy:
      - origin-when-cross-origin
      Server:
      - Finatra
      Set-Cookie:
      - ncbi_sid=9E7725A350D33AFB_E812SID; domain=.nih.gov; path=/; expires=Sat, 12
        Apr 2025 19:08:05 GMT
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Transfer-Encoding:
      - chunked
      X-RateLimit-Limit:
      - '3'
      X-RateLimit-Remaining:
      - '1'
      X-UA-Compatible:
      - IE=Edge
      X-XSS-Protection:
      - 1; mode=block
      content-encoding:
      - gzip
    status:
      code: 200
      message: OK
version: 1
